| 國立成功大學 |
2022-09-15 |
Biomass torrefaction: An overview of process and technology assessment based on global readiness level
|
Kota;Bharadwaj, Karthikeya;Shenbagaraj;Shribalaji;Sharma;Kumar, Pankaj;Sharma;Kumar, Amit;Ghodke;Kumar, Praveen;Chen;Wei-Hsin |
| 國立成功大學 |
2022-09-15 |
Seismic behaviour of full-scale lightly reinforced concrete columns under high axial loads
|
Huy;Anh, Pham Phu;Yuen;YP, Terry;Hung;Chung-Chan;Mosalam;Khalid, M. |
| 國立成功大學 |
2022-09-15 |
All-optical, tunable, V- and W-band microwave generation using semiconductor lasers at period-one nonlinear dynamics with asymmetric mutual injection stabilization
|
Tseng;Chin-hao;Liao;Bin-kai;Hwang;Sheng-kwang |
| 國立成功大學 |
2022-09-15 |
Long-term consumption of the sugar substitute sorbitol alters gut microbiome and induces glucose intolerance in mice
|
Li;Chung-Hao;Wang;Chung-Teng;Lin;Ying-Ju;Kuo;Hsin-Yu;Wu;Juei-Seng;Hong;Tzu-Chun;Chang;Chih-Jen;Wu;Hung-Tsung |
| 國立成功大學 |
2022-09-15 |
Direct Measurement of Electron Cyclotron Emission during High Guide Field Magnetic Reconnection
|
Inomoto;Michiaki;Kondo;Kyohei;Kawamori;Eiichirou;Igami;Hiroe |
| 國立成功大學 |
2022-09-15 |
Adsorption and Desorption Behaviors of Sr on Montmorillonite: A Triple Sr Isotope Perspective
|
Liu;Hou-Chun;Hsieh;Jia-You;Chen;Yen-Hong;You;Chen-Feng;Jiang;Wei-Teh;Wen;Hsin-Yi |
| 國立成功大學 |
2022-09-15 |
Comparing different surface modifications of zinc oxide nanoparticles in the developmental toxicity of zebrafish embryos and larvae
|
Chen;Zi-Yu;Yang;Yi-Chun;Wang;Bour-;Jr;Cheng;Fong-Yu;Lee;Yen-Ling;Lee;Yu-Hsuan;Wang;Ying-Jan |
| 中國文化大學 |
2022-09-15 |
Comparing different surface modifications of zinc oxide nanoparticles in the developmental toxicity of zebrafish embryos and larvae
|
Chen, Zi-Yu; Yang, Yi-Chun; Wang, Bour-Jr; Cheng, Fong-Yu; Lee, Yen-Ling; Lee, Yu-Hsuan; Wang, Ying-Jan |
| 淡江大學 |
2022-09-15 |
Biochar aerogel decorated with thiophene S manipulated 5-membered rings boosts nitrogen flxation
|
Chen, Xiaokang;Zhang, Lijie;Xu, Wenjia;Ding, Xin;Chen, Shuai;She, Xilin;Guo, Xiangxin;Dong, Chung-Li;Huang, Yucheng;Zhang, Lixue;Shen, Shaohua;Yang, Dongjiang |
| 國立成功大學 |
2022-09-15 |
從現代到後現代——洪根深水墨創作發展之研究
|
黃芊育; Huang, Chien-Yu |
| 國立成功大學 |
2022-09-15 |
基於局部場轉換之磁振造影大腦組織磁化率定量
|
黃德容; Huang, De-Rong |
| 國立成功大學 |
2022-09-15 |
利用參照物理特性之深度學習技術達成磁振大腦組織磁化率定量
|
鄭至善; Cheng, Jhih-Shan |
| 輔英科技大學 |
2022-09-15 |
The Waxing, Waning, and Predictors of Humoral Responses to Vector-Based SARS-CoV-2 Vaccine in Hemodialysis Patients
|
Fu, Chung-Ming;Tsai, Kai-Fan;Kuo, i-Hung;Wu, Chien-Hsing;Yu, Ching-I;You, Huey-Ling;Lee, Chien-Te |
| 淡江大學 |
2022-09-15 |
樂活創意，遠而無距--疫情下的居家體育課
|
郭馥滋 |
| 美和科技大學 |
2022-09-15 |
問題導向學習融入「方案設計與評估」課程之教學實踐研究
|
王明鳳 |
| 美和科技大學 |
2022-09-15 |
不只是教室，是在學習的路上--跨領域多元教學模式於 銀髮健康管理課程學習成效之教學研究探討
|
楊燦 |
| 臺大學術典藏 |
2022-09-15T01:08:43Z |
Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy
|
Huang T.-C.; Liang C.-W.; Li Y.-I.; Guo J.-C.; Chia-Chi Lin; Chen Y.-J.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-09-15T01:08:44Z |
Immunotherapy in anaplastic thyroid cancer: Case series
|
Shih S.-R.; Chen K.-H.; Lin K.-Y.; Yang P.-C.; Chen K.-Y.; Wang C.-W.; Chen C.-N.; Lin C.-F.; Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-15T01:08:44Z |
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
|
Italiano A.; Cassier P.A.; Chia-Chi Lin; Alanko T.; Peltola K.J.; Gazzah A.; Shiah H.-S.; Calvo E.; Cervantes A.; Roda D.; Tosi D.; Gao B.; Millward M.; Warburton L.; Tanner M.; Englert S.; Lambert S.; Parikh A.; Afar D.E.; Vosganian G.; Moreno V. |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali P.A.; Chia-Chi Lin; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; Shen Y.-C.; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J. |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies
|
Shimizu T.; Kuboki Y.; Chia-Chi Lin; Yonemori K.; Yanai T.; Faller D.V.; Dobler L.; Gupta N.; Sedarati F.; Kim K.-P. |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; Chia-Chi Lin; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J. |
| 臺大學術典藏 |
2022-09-15T01:08:46Z |
Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan with concomitant ritonavir or itraconazole in patients with HER2-expressing advanced solid tumors
|
Takahashi S.; Karayama M.; Takahashi M.; Watanabe J.; Minami H.; Yamamoto N.; Kinoshita I.; Chia-Chi Lin; Im Y.-H.; Achiwa I.; Kamiyama E.; Okuda Y.; Lee C.; Bang Y.-J. |
| 臺大學術典藏 |
2022-09-15T01:08:46Z |
Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan
|
Yin O.; Iwata H.; Chia-Chi Lin; Tamura K.; Watanabe J.; Wada R.; Kastrissios H.; AbuTarif M.; Garimella T.; Lee C.; Zhang L.; Shahidi J.; LaCreta F. |
| 臺大學術典藏 |
2022-09-15T01:08:46Z |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-15T01:08:47Z |
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Brose M.S.; Robinson B.; Sherman S.I.; Krajewska J.; Chia-Chi Lin; Vaisman F.; Hoff A.O.; Hitre E.; Bowles D.W.; Hernando J.; Faoro L.; Banerjee K.; Oliver J.W.; Keam B.; Capdevila J. |
| 臺大學術典藏 |
2022-09-15T01:08:47Z |
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
|
Subbiah V.; Hu M.I.; Wirth L.J.; Schuler M.; Mansfield A.S.; Curigliano G.; Brose M.S.; Zhu V.W.; Leboulleux S.; Bowles D.W.; Baik C.S.; Adkins D.; Keam B.; Matos I.; Garralda E.; Gainor J.F.; Lopes G.; Chia-Chi Lin; Godbert Y.; Sarker D.; Miller S.G.; Clifford C.; Zhang H.; Turner C.D.; Taylor M.H. |
| 臺大學術典藏 |
2022-09-15T01:08:47Z |
Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites
|
Guo J.-C.; Lin C.-Y.; Chia-Chi Lin; Huang T.-C.; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2022-09-15T01:08:48Z |
Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors
|
Curigliano G.; Gelderblom H.; Mach N.; Doi T.; Tai D.; Forde P.M.; Sarantopoulos J.; Bedard P.L.; Chia-Chi Lin; Stephen Hodi F.; Wilgenhof S.; Santoro A.; Sabatos-Peyton C.A.; Longmire T.A.; Xyrafas A.; Sun H.; Gutzwiller S.; Manenti L.; Naing A. |
| 臺大學術典藏 |
2022-09-15T01:08:48Z |
Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium
|
Shimizu T.; Kim D.-W.; Loong H.H.; Chia-Chi Lin; Ng M.C.H.; Yamamoto N.; Ma B.; Tan D.S.W. |
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia
|
Chia-Chi Lin; Doi T.; Muro K.; Hou M.-M.; Esaki T.; Hara H.; Chung H.C.; Helwig C.; Dussault I.; Osada M.; Kondo S. |
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors
|
Lewis J.H.; Gelderblom H.; van de Sande M.; Stacchiotti S.; Healey J.H.; Tap W.D.; Wagner A.J.; Pousa A.L.; Druta M.; Chia-Chi Lin; Baba H.A.; Choi Y.; Wang Q.; Shuster D.E.; Bauer S. |
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors
|
Shiah H.-S.; Chiang N.-J.; Chia-Chi Lin; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T. |
| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Endoscopic ultrasound ablation in a patient with multiple metastatic pancreatic tumors from adrenocorticotropic hormone-producing thymic neuroendocrine neoplasm
|
Chang L.-K.; Chen K.-C.; Cheng M.-F.; Chia-Chi Lin; Wang H.-P.; Sung C.-T.; Chen J.-H.; Yen R.-F.; Hsu C.-L.; Shih S.-R. |
| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
|
Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Chia-Chi Lin; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; Chia-Chi Lin; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J. |
| 臺大學術典藏 |
2022-09-15T01:08:51Z |
Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves’ Orbitopathy
|
Shih S.-R.; Liao S.-L.; Shih C.-W.; Wei Y.-H.; Lu T.-X.; Chou C.-H.; Yen E.-Y.; Chang Y.-C.; Chia-Chi Lin; Chi Y.-C.; Yang W.-S.; Tsai F.-C. |
| 臺大學術典藏 |
2022-09-15T01:08:51Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Chia-Chi Lin; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; Hsu C. |
| 臺大學術典藏 |
2022-09-15T01:08:51Z |
Clinical development of colony-stimulating factor 1 receptor (Csf1r) inhibitors
|
Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-15T01:08:52Z |
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer
|
Bible K.C.; Menefee M.E.; Chia-Chi Lin; Millward M.J.; Maples W.J.; Goh B.C.; Karlin N.J.; Kane M.A.; Adkins D.R.; Molina J.R.; Donehower R.C.; Lim W.-T.; Flynn P.J.; Richardson R.L.; Traynor A.M.; Rubin J.; Lorusso P.M.; Smallridge R.C.; Burton J.K.; Suman V.J.; Kumar A.; Voss J.S.; Rumilla K.M.; Kipp B.R.; Chintakuntlawar A.V.; Harris P.; Erlichman C. |
| 臺大學術典藏 |
2022-09-15T01:08:52Z |
Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
|
Bang Y.-J.; Golan T.; Dahan L.; Fu S.; Moreno V.; Park K.; Geva R.; De Braud F.; Wainberg Z.A.; Reck M.; Goff L.; Laing N.; Mi G.; Oliveira J.M.; Wasserstrom H.; Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-15T01:08:53Z |
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC
|
Zhu V.W.; Lin Y.-T.; Kim D.-W.; Loong H.H.; Nagasaka M.; To H.; Ang Y.L.-E.; Ock C.-Y.; Tchekmedyian N.; Ou S.-H.I.; Syn N.L.; Reungwetwattana T.; Chia-Chi Lin; Soo R.A. |
| 臺大學術典藏 |
2022-09-15T01:08:53Z |
PD-1 blockade in anaplastic thyroid carcinoma
|
Capdevila J.; Wirth L.J.; Ernst T.; Aix S.P.; Chia-Chi Lin; Ramlau R.; Butler M.O.; Delord J.-P.; Gelderblom H.; Ascierto P.A.; Fasolo A.; F?hrer D.; H?tter-Kr?nke M.L.; Forde P.M.; Wrona A.; Santoro A.; Sadow P.M.; Szpakowski S.; Wu H.; Bostel G.; Faris J.; Cameron S.; Varga A.; Taylor M. |
| 臺大學術典藏 |
2022-09-15T01:08:54Z |
Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma
|
Si L.; Zhang X.; Shin S.J.; Fan Y.; Chia-Chi Lin; Kim T.M.; Dechaphunkul A.; Maneechavakajorn J.; Wong C.S.; Ilankumaran P.; Lee D.-Y.; Gasal E.; Li H.; Guo J. |
| 臺大學術典藏 |
2022-09-15T01:08:54Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Chia-Chi Lin; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-09-15T01:08:55Z |
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
|
Paz-Ares L.; Kim T.M.; Vicente D.; Felip E.; Lee D.H.; Lee K.H.; Chia-Chi Lin; Flor M.J.; Di Nicola M.; Alvarez R.M.; Dussault I.; Helwig C.; Ojalvo L.S.; Gulley J.L.; Cho B.C. |
| 臺大學術典藏 |
2022-09-15T01:08:56Z |
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
|
Desai J.; Deva S.; Lee J.S.; Chia-Chi Lin; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M. |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
|
Peters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; Chia-Chi Lin; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D. |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Chia-Chi Lin; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors
|
Strickler J.H.; LoRusso P.; Salgia R.; Kang Y.-K.; Yen C.J.; Chia-Chi Lin; Ansell P.; Motwani M.; Wong S.; Yue H.; Wang L.; Reilly E.; Afar D.; Naumovski L.; Ramanathan R.K. |
